Define your path
ADCETRIS plus AVD is approved to treat adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma.
Before discussing treatment and making a decision with your doctor, learn more about the benefits and risks of ADCETRIS plus AVD and see results from the ECHELON-1 study.
About Stage 3 or 4 classical Hodgkin lymphoma
Classical Hodgkin lymphoma, also called Hodgkin’s lymphoma, Hodgkin’s disease, or Hodgkin’s, is a type of cancer of the blood. It starts when lymphocytes, a type of white blood cell, grow out of control.
This video provides an introductory look into Stage 3 and 4 classical Hodgkin lymphoma, including what it is, how it affects the body, risk factors, and common symptoms. Whether you’re newly diagnosed or are a caregiver looking to learn more about this condition, this overview is designed to help you feel more informed.
If you’ve recently been diagnosed with Stage 3 or 4 classical Hodgkin lymphoma, your first treatment choice matters.
Mary Ann’s treatment journey
ADCETRIS will not work for everyone.
ADCETRIS is a well-established treatment backed by over a decade of clinical data
- Nearly 1700 patients with certain types of lymphoma received treatment with ADCETRIS across 8 clinical trials
- Over 67,000 patients in the US and over 183,000 patients worldwide have been treated with ADCETRIS since 2011
Healthcare providers have relied on the extensive clinical study data of ADCETRIS when treating their patients. Researchers continue to investigate ADCETRIS in clinical trials today.
Talk to your doctor about ADCETRIS
ADCETRIS patient brochure
Doctor Discussion Guide
It's important to ask questions and share concerns about ADCETRIS treatment with a doctor. The Doctor Discussion Guide can help you navigate the conversation, so you get the most out of your visit. Take this printable PDF with you to your next appointment.
Glossary
ABVD: A combination of 4 chemotherapies—Adriamycin, bleomycin, vinblastine, and dacarbazine.
AVD: A combination of 3 chemotherapies—Adriamycin, vinblastine, and dacarbazine.